CA1112572A - Injectable chloramphenicol composition - Google Patents
Injectable chloramphenicol compositionInfo
- Publication number
- CA1112572A CA1112572A CA307,371A CA307371A CA1112572A CA 1112572 A CA1112572 A CA 1112572A CA 307371 A CA307371 A CA 307371A CA 1112572 A CA1112572 A CA 1112572A
- Authority
- CA
- Canada
- Prior art keywords
- chloramphenicol
- composition
- pvp
- composition according
- injectable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005091 chloramphenicol Drugs 0.000 title claims abstract description 31
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims abstract description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- -1 glycerolformal Chemical compound 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229940074076 glycerol formal Drugs 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 239000007972 injectable composition Substances 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 229920003081 Povidone K 30 Polymers 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000193803 Therea Species 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
AN INJECTABLE CHLORAMPHENICOL COMPOSITION
ABSTRACT
The present invention relates to a stable injectable chloramphenicol composition having preferably a high content of chloramphenicol. Said composition comprises chloramphenicol, N-methylpyrrolidone, PVP and, if desired, a pharmaceutically acceptable solvent which is miscible with N-methylpyrrolidone.
ABSTRACT
The present invention relates to a stable injectable chloramphenicol composition having preferably a high content of chloramphenicol. Said composition comprises chloramphenicol, N-methylpyrrolidone, PVP and, if desired, a pharmaceutically acceptable solvent which is miscible with N-methylpyrrolidone.
Description
. . .
`~; The present invention relate~ to a stable injectable .. chloramphenicol composition having a high content oP chlor-amphenicol.
.. ~- Chloramphenicol is utilised at present mainl~ for :,;.
... veteri~ary purpo~e~. It i desired to admin1ster to a large il.,.
animal a compo~ition having a rather high content o~ chlor-amphe~icol~ Said large amount o~ chloramphen1col should e3hib~t oonstant blood level~ and be active for quite a long period o~ time~ So ~ar there ha~ been injected sodlum succinate o~ chloramph~nlcol i~ a concentration of 25% and there are al~o known some ~njectable compositions whioh compri~e up to 25% o~ active compound. Howe~er, these compositions are : .
not Plway~ sati~actory, i.e~ in particular they are unstable ` and ha~e a relatively short shelf life, and it was therefore de~irable to de~elop compoaitions which would have higher concentrations of chloramphenicol and would have the desired properties, i.e~ exhibit con~tant blood levels and have a long : shel~ llie~
It has been ~oud that if chloramphenicol is dissolved .~ in N-methylpyrrolidone there may be prepared composition~
~ having a higher concsntration o~ chloramphenicol(about 50%).
.~ ; Howe~er, these co~po~itions had the following drawbacks:
:
a~ Brratic blcod le~els were obtained~
:~ b~ Pain and ~rritation were cau~ed to the animal treated with : said iniection.
., :
.: ~
:
:,' . ~
..
, ,~ i :-~
`~; The present invention relate~ to a stable injectable .. chloramphenicol composition having a high content oP chlor-amphenicol.
.. ~- Chloramphenicol is utilised at present mainl~ for :,;.
... veteri~ary purpo~e~. It i desired to admin1ster to a large il.,.
animal a compo~ition having a rather high content o~ chlor-amphe~icol~ Said large amount o~ chloramphen1col should e3hib~t oonstant blood level~ and be active for quite a long period o~ time~ So ~ar there ha~ been injected sodlum succinate o~ chloramph~nlcol i~ a concentration of 25% and there are al~o known some ~njectable compositions whioh compri~e up to 25% o~ active compound. Howe~er, these compositions are : .
not Plway~ sati~actory, i.e~ in particular they are unstable ` and ha~e a relatively short shelf life, and it was therefore de~irable to de~elop compoaitions which would have higher concentrations of chloramphenicol and would have the desired properties, i.e~ exhibit con~tant blood levels and have a long : shel~ llie~
It has been ~oud that if chloramphenicol is dissolved .~ in N-methylpyrrolidone there may be prepared composition~
~ having a higher concsntration o~ chloramphenicol(about 50%).
.~ ; Howe~er, these co~po~itions had the following drawbacks:
:
a~ Brratic blcod le~els were obtained~
:~ b~ Pain and ~rritation were cau~ed to the animal treated with : said iniection.
., :
.: ~
:
:,' . ~
..
, ,~ i :-~
2 ~ ~ h~
~ or these reaaon6 said compositions were not applicable~
It has ~ow surprisingly been fo~nd that with the ~ddition of a certain amount o~ polyvinyl pyrrolidone(PVP) to said com-poaltion said drawback~ are overcome~ ~hi~ has been surprl~ing as it could not be e~pected that PVP would cau~e a const~t blood level and in particular that it would dispel the pai~
and irritation~ The shelf life o~ said composition~ iR at lea~t one year.
The pre~ent invention thus con~i~t~ i~ an injectable compo~ition c~mpris~ng chloramphenicol, ~-methylpyrrolidone, PVP and, i~ desired, a pharmaoeutically acceptable ~olvent whiCh is miscible with N-~ethylpyrrolidoneO
~ ompo~itions according to the present invention may compr~es al80~ ii de~ired, only small amount of chloramphe n~col~ ~owever, they ~hould contain preferably at least 30~o of chloramphe~icol and especi~1ly 40-60~o(all percentages are glv9~ herein ~ight/~olume)0 Ccmposition~ according to the pre~ont invention havlng a lower content of chloramphenlcol are also ~uch bett~r than tho~e commercially available a~
they are mu~h more stable.
The ~mount o~ the PVP varles and it should be be~ween 4-20~ pre~6rably between 5 lOYo of the entire composition.
Other solvents, i~ required, are utilised as dilu~t in order to get the required concentration of the composit~cn.
~ suitable solvents one should mention water, ethanol and in particular, certain glycols, or deri~atives thereoft e.g.
propyl~neglycol, glycerol-formal, tertaglycol, polyethylene-,., ~l~col, ~t~
!
5'7
~ or these reaaon6 said compositions were not applicable~
It has ~ow surprisingly been fo~nd that with the ~ddition of a certain amount o~ polyvinyl pyrrolidone(PVP) to said com-poaltion said drawback~ are overcome~ ~hi~ has been surprl~ing as it could not be e~pected that PVP would cau~e a const~t blood level and in particular that it would dispel the pai~
and irritation~ The shelf life o~ said composition~ iR at lea~t one year.
The pre~ent invention thus con~i~t~ i~ an injectable compo~ition c~mpris~ng chloramphenicol, ~-methylpyrrolidone, PVP and, i~ desired, a pharmaoeutically acceptable ~olvent whiCh is miscible with N-~ethylpyrrolidoneO
~ ompo~itions according to the present invention may compr~es al80~ ii de~ired, only small amount of chloramphe n~col~ ~owever, they ~hould contain preferably at least 30~o of chloramphe~icol and especi~1ly 40-60~o(all percentages are glv9~ herein ~ight/~olume)0 Ccmposition~ according to the pre~ont invention havlng a lower content of chloramphenlcol are also ~uch bett~r than tho~e commercially available a~
they are mu~h more stable.
The ~mount o~ the PVP varles and it should be be~ween 4-20~ pre~6rably between 5 lOYo of the entire composition.
Other solvents, i~ required, are utilised as dilu~t in order to get the required concentration of the composit~cn.
~ suitable solvents one should mention water, ethanol and in particular, certain glycols, or deri~atives thereoft e.g.
propyl~neglycol, glycerol-formal, tertaglycol, polyethylene-,., ~l~col, ~t~
!
5'7
- 3 -~,.";.
,j .
.~
' .~. .
'. The present invention will now be illustrated with ,` reference to the following examples without being restricted by them.
The composition of the present invention were prepared as follows in all exampleæ:
:
,; . The chloramphenicol wa~ dis~olved in N-methylpyrrolidone.
-~ Therea~ter the PVP was added and finally the additional ~olvent, i~ any, was admi~ed~
The PYP utilised i~ a product of General Aniline and - Fil~ Corporation.The K numbers are derived from viRcosity.
-: Exam~ls 1 Chloramphenicol 50.0 g N-Methylpyrrolidone 40.0 g . ; PVP K30 6.0 g Propyleneglycol enough to make lOOoO ml .. At the end of two years ~torage at room temperature ,, only 3.5% of the chloramphenicol degradedO
; : The volume needed of th~ composition (called ~50%")'',.,', to be in~ected to a ruminant for aohieving a dose level :' - of 50 ~ kg was compared with the ~ollowing composition:
.. Chloramphenicol 20 g ~~ Glycerol~ormsl 80 g Water enough to make 100 ml ~: ~he shelf life of the 20/o composition was leEs than 2 mcnths (the degradation of chloramphenicol was about 40%)~
~he results are given in Table I, which show comparitive . blood le~el~ o~ chloramphenicol af~er parenteral administration ~` of 50 m ~ kg of each of the composition~.
, ~i"
` ~
: `
,j .
.~
' .~. .
'. The present invention will now be illustrated with ,` reference to the following examples without being restricted by them.
The composition of the present invention were prepared as follows in all exampleæ:
:
,; . The chloramphenicol wa~ dis~olved in N-methylpyrrolidone.
-~ Therea~ter the PVP was added and finally the additional ~olvent, i~ any, was admi~ed~
The PYP utilised i~ a product of General Aniline and - Fil~ Corporation.The K numbers are derived from viRcosity.
-: Exam~ls 1 Chloramphenicol 50.0 g N-Methylpyrrolidone 40.0 g . ; PVP K30 6.0 g Propyleneglycol enough to make lOOoO ml .. At the end of two years ~torage at room temperature ,, only 3.5% of the chloramphenicol degradedO
; : The volume needed of th~ composition (called ~50%")'',.,', to be in~ected to a ruminant for aohieving a dose level :' - of 50 ~ kg was compared with the ~ollowing composition:
.. Chloramphenicol 20 g ~~ Glycerol~ormsl 80 g Water enough to make 100 ml ~: ~he shelf life of the 20/o composition was leEs than 2 mcnths (the degradation of chloramphenicol was about 40%)~
~he results are given in Table I, which show comparitive . blood le~el~ o~ chloramphenicol af~er parenteral administration ~` of 50 m ~ kg of each of the composition~.
, ~i"
` ~
: `
- 4 -TABLE I
. ~__ . . . . .... .
~'ormulatio~ Calf of ~we of ~ow of ~ow of ::: 50 kg 65 kg 500 kg 650 kg 50% 5 6~5 50 65 .
Si~llar compari ons with composition~ having various concentrations o~ chloramphenicol showed the superiority of the 50% composition.
Moreover, the mean serum chloramphenicol concentrations over a certain period of time ~ollowing a ~ingle intramuscular ;: in~20tion o~ said formulations were compared.
The re~ults are æhown in the accompanying drawings .- in which:
~ igol ~hows the mean serum concentration of c~lves at a dose level oi 50 m ~ kgO
.~ Fig.2 ehow the mean serum concentration at cows ,~ .
: at a do~e level of 30 mg/kg; a~d Fig.~ a~o~s the mean ~erum concentration at ewes at '~ . at a do~e level of 50 mg/kg.
,~ The t~t~ ~ere per~ormed by k~own method~ (3ee, for e~ample, Glazko,(s), Set.al. ArchO Biochem. 23, 411-418,1949 . and Zi~.6. et alO Zbl,Vet.MedO(A) 207801-811,1973).
~' am~le 2 `.- Chloramphenicol 10.0 g .- N-Methylpyrrolidine 3000 g PYP ~15 6~0 g . Propyleneglyool enough to make 100.0 ml .;
.
.'` ', .
` ::
h~Z
. ,, ~` Example 3 :~: Chlor~mphenicol 80.0 g .. PVP K15 6.0 g N-Methylpyrrolidone enough to make 100.0 ml ~ Example 4 m: Chloramphenicol 50.0 g ,.
~, N-Methylpyrrolidone 40.0 g PVP K30 10,0 g : Glycerol~o~mal enough to make 100.() ~1 Example 5 Chloramphenicol 50.0 g N-Methylpyrrolidone 40.0 g PVP K30 1.0 g ; . ..:
.. Tetraglycol enough to make100.0 ml . Example 6 . ~
; - Chloramphenicol 40.0 g : ~ N-Methylpyrrolidone 40.0 g :....
:~ PYP K15 15.0 g ., -: .
. Polyethyleneglycol 300 enough to make 100.0 ml `~ 20 Example 7 . Chloramphenicol 30.0 g ;:- N-Methylpyrrolidone 40.0 g .:
:~. PVP K15 20.0 g Ethanol 95% enough to make100.0 ml Example 8 ' ~
Chloramphenicol 30 g N-Methylpyrrolidone 40 g ~VP K15 20 g ~ater enough to ~ake 100 ml.
: ~ - 5 -::
'
. ~__ . . . . .... .
~'ormulatio~ Calf of ~we of ~ow of ~ow of ::: 50 kg 65 kg 500 kg 650 kg 50% 5 6~5 50 65 .
Si~llar compari ons with composition~ having various concentrations o~ chloramphenicol showed the superiority of the 50% composition.
Moreover, the mean serum chloramphenicol concentrations over a certain period of time ~ollowing a ~ingle intramuscular ;: in~20tion o~ said formulations were compared.
The re~ults are æhown in the accompanying drawings .- in which:
~ igol ~hows the mean serum concentration of c~lves at a dose level oi 50 m ~ kgO
.~ Fig.2 ehow the mean serum concentration at cows ,~ .
: at a do~e level of 30 mg/kg; a~d Fig.~ a~o~s the mean ~erum concentration at ewes at '~ . at a do~e level of 50 mg/kg.
,~ The t~t~ ~ere per~ormed by k~own method~ (3ee, for e~ample, Glazko,(s), Set.al. ArchO Biochem. 23, 411-418,1949 . and Zi~.6. et alO Zbl,Vet.MedO(A) 207801-811,1973).
~' am~le 2 `.- Chloramphenicol 10.0 g .- N-Methylpyrrolidine 3000 g PYP ~15 6~0 g . Propyleneglyool enough to make 100.0 ml .;
.
.'` ', .
` ::
h~Z
. ,, ~` Example 3 :~: Chlor~mphenicol 80.0 g .. PVP K15 6.0 g N-Methylpyrrolidone enough to make 100.0 ml ~ Example 4 m: Chloramphenicol 50.0 g ,.
~, N-Methylpyrrolidone 40.0 g PVP K30 10,0 g : Glycerol~o~mal enough to make 100.() ~1 Example 5 Chloramphenicol 50.0 g N-Methylpyrrolidone 40.0 g PVP K30 1.0 g ; . ..:
.. Tetraglycol enough to make100.0 ml . Example 6 . ~
; - Chloramphenicol 40.0 g : ~ N-Methylpyrrolidone 40.0 g :....
:~ PYP K15 15.0 g ., -: .
. Polyethyleneglycol 300 enough to make 100.0 ml `~ 20 Example 7 . Chloramphenicol 30.0 g ;:- N-Methylpyrrolidone 40.0 g .:
:~. PVP K15 20.0 g Ethanol 95% enough to make100.0 ml Example 8 ' ~
Chloramphenicol 30 g N-Methylpyrrolidone 40 g ~VP K15 20 g ~ater enough to ~ake 100 ml.
: ~ - 5 -::
'
Claims (12)
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An injectable composition comprising chloramphenicol, N-methyl-pyrrolidone and PVP.
2. The composition of claim 1, further including a pharmaceutically acceptable solvent which is miscible with N-methylpyrrolidone.
3. A composition according to claim 1 or 2, wherein the amount of chloramphenicol is at least 30%.
4. A composition according to claim 1 or 2, wherein the amount of chloramphenicol is 40-60%.
5. A composition according to claim 1 or 2, wherein the amount of PVP is 4-20%.
6. A composition according to claim 1 or 2, wherein the amount of PVP is 5-10%.
7. A composition according to claim 2, wherein the additional solvent is water.
8. A composition according to claim 2, wherein the additional solvent is ethanol.
9. A composition according to claim 2, wherein the additional solvent is a glycol or a derivative thereof.
10. A composition according to claim 9, wherein the glycol is selected among the group comprising propyleneglycol, glycerolformal, tetraglycol, poly-ethyleneglycol.
11. A method for the preparation of an injectable composition as defined in claim 1, wherein the chloramphenicol is dissolved in the N-methyl-pyrrolidone, and PVP is added to the solution.
12. The method for the preparation of an injectable composition as defined in claim 2, wherein the chloramphenicol is dissolved in the N-methyl-pyrrolidone, the PVP is added to the solution, and the pharmaceutically acceptable solvent is added.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL52533A IL52533A (en) | 1977-07-15 | 1977-07-15 | Injectable chloramphenicol composition |
| IL52533 | 1977-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1112572A true CA1112572A (en) | 1981-11-17 |
Family
ID=11049656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA307,371A Expired CA1112572A (en) | 1977-07-15 | 1978-07-14 | Injectable chloramphenicol composition |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS5420125A (en) |
| AT (1) | AT360149B (en) |
| AU (1) | AU3752578A (en) |
| BE (1) | BE869001A (en) |
| CA (1) | CA1112572A (en) |
| DE (1) | DE2829408A1 (en) |
| FR (1) | FR2397191A1 (en) |
| GB (1) | GB2000970B (en) |
| IE (1) | IE47126B1 (en) |
| IL (1) | IL52533A (en) |
| NL (1) | NL7807641A (en) |
| NZ (1) | NZ187683A (en) |
| ZA (1) | ZA783671B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3064250D1 (en) * | 1979-07-02 | 1983-08-25 | Pfizer | Long acting sulfonamide injectable compositions |
| NL8002636A (en) * | 1980-05-08 | 1981-12-01 | Gist Brocades Nv | SOLOATE OF AMOXICILLINE, METHOD FOR PREPARING IT AND METHOD FOR PREPARING INJECTION PREPARATIONS FROM THIS SOLVATE |
| NL178941C (en) * | 1982-06-15 | 1986-06-16 | Aesculaap Bv | PROCESS FOR PREPARING AN AQUEOUS OXYTETRACYCLINE PREPARATION. |
| JPS6031189A (en) * | 1983-07-30 | 1985-02-16 | カシオ計算機株式会社 | musical tone generator |
| US4696814A (en) * | 1985-08-21 | 1987-09-29 | Warner-Lambert Company | Parenteral phenytoin compositions |
| IT1197481B (en) * | 1986-09-15 | 1988-11-30 | Zambon Spa | PHARMACEUTICAL PREPARATION FOR VETERINARY USE |
| US20030068339A1 (en) * | 2001-10-02 | 2003-04-10 | Phoenix Scientific, Inc. | Veterinary florfenicol formulation that is syringeable under cold weather conditions |
| JP5017122B2 (en) | 2004-12-21 | 2012-09-05 | インターベツト・インターナシヨナル・ベー・ベー | Injectable veterinary composition |
| CN113694018A (en) * | 2021-09-08 | 2021-11-26 | 海南制药厂有限公司制药二厂 | Chloramphenicol injection and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1538903A (en) * | 1975-04-11 | 1979-01-24 | Nelson Res & Dev | Carrier for a topically applied physiologically active agent or cosmetic agent |
-
1977
- 1977-07-15 IL IL52533A patent/IL52533A/en unknown
-
1978
- 1978-06-27 ZA ZA00783671A patent/ZA783671B/en unknown
- 1978-06-27 NZ NZ187683A patent/NZ187683A/en unknown
- 1978-06-28 AU AU37525/78A patent/AU3752578A/en active Pending
- 1978-07-04 FR FR7819873A patent/FR2397191A1/en active Granted
- 1978-07-05 DE DE19782829408 patent/DE2829408A1/en not_active Withdrawn
- 1978-07-14 IE IE1425/78A patent/IE47126B1/en unknown
- 1978-07-14 CA CA307,371A patent/CA1112572A/en not_active Expired
- 1978-07-14 AT AT511878A patent/AT360149B/en not_active IP Right Cessation
- 1978-07-14 JP JP8665578A patent/JPS5420125A/en active Pending
- 1978-07-14 GB GB7829921A patent/GB2000970B/en not_active Expired
- 1978-07-14 BE BE189287A patent/BE869001A/en unknown
- 1978-07-17 NL NL7807641A patent/NL7807641A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2000970A (en) | 1979-01-24 |
| BE869001A (en) | 1979-01-15 |
| DE2829408A1 (en) | 1979-02-01 |
| ZA783671B (en) | 1979-06-27 |
| IL52533A0 (en) | 1977-10-31 |
| IE781425L (en) | 1979-01-15 |
| NZ187683A (en) | 1981-03-16 |
| AU3752578A (en) | 1980-01-03 |
| GB2000970B (en) | 1982-03-17 |
| ATA511878A (en) | 1980-05-15 |
| AT360149B (en) | 1980-12-29 |
| JPS5420125A (en) | 1979-02-15 |
| IE47126B1 (en) | 1983-12-28 |
| IL52533A (en) | 1980-01-31 |
| FR2397191B1 (en) | 1981-12-31 |
| FR2397191A1 (en) | 1979-02-09 |
| NL7807641A (en) | 1979-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1112572A (en) | Injectable chloramphenicol composition | |
| KR880002366B1 (en) | Non-aqueous ivermectin formulation | |
| GEP19991856B (en) | Taxoid-Based Compositions for Injection | |
| KR900012625A (en) | Cyclosporingane formulations | |
| JP4257870B2 (en) | Avermectin-containing and milbemycin-containing preparations based on castor oil | |
| BR9710955A (en) | Cocoa extract compounds and methods for their production and use | |
| GB2126588A (en) | A method for stabilizing tumor necrosis factor and a stable aqueous solution or powder containing the same | |
| DE60017582D1 (en) | TRICYCLIC DERIVATIVES OF PYRAZOL CARBOXYLIC ACID, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| HU219477B (en) | Pharmaceutical compositions containing rapamycin for intravenous injection administration and method of preparation | |
| KR890700125A (en) | New benzimidazole derivatives, preparation method thereof and pharmaceutical composition containing the compound | |
| US5116949A (en) | Benzoyl urea compound-albumin complex | |
| HU219236B (en) | Pharmaceutical compositions containing rapamycin suitable for i.v. administration and process for the preparation thereof | |
| WO2006126214A2 (en) | Injectable compositions and process for preparation of such compositions | |
| IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
| EP0431828B1 (en) | Improvements relating to the administration of pharmaceutical agents | |
| TNSN00145A1 (en) | STREPTOGRAMIN DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM | |
| JPS62158209A (en) | Liquid ubiquinone drug composition | |
| US5214052A (en) | Method for dissolving arginineamides and pharmaceutical compositions containing them | |
| KR20100019979A (en) | Pharmaceutical composition | |
| US6020359A (en) | Pharmaceutical composition | |
| EP0433909A2 (en) | Formulation | |
| Pacifici et al. | Metabolic interaction between morphine and various benzodiazepines | |
| DE3563048D1 (en) | 2-pyridine-thiol derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| IL40050A (en) | Compositions for treating microbial infections containing piperidine derivatives | |
| RU95107147A (en) | Cyclohexanecarboxylic acid derivatives, mixture of isomers thereof or individual isomers and physiologically tolerable salts, and pharmaceutical composition having activity which inhibits enzymic glucose-phosphotase complex of liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |